1. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. Issue 3 (March 2022) Authors: Smith, Matthew R; Scher, Howard I; Sandhu, Shahneen; Efstathiou, Eleni; Lara, Primo N; Yu, Evan Y; George, Daniel J; Chi, Kim N; Saad, Fred; Ståhl, Olof; Olmos, David; Danila, Daniel C; Mason, Gary E; Espina, Byron M; Zhao, Xin; Urtishak, Karen A; Francis, Peter; Lopez-Gitlitz, Angela; Fizazi, Ka... Journal: Lancet oncology Issue: Volume 23:Issue 3(2022) Page Start: 362 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗